Description
Neurofilament L (NF-L) is one of four subunits that form NFs, which are type III intermediate filament proteins that enable axonal growth, maintain structure, and facilitate nerve conduction.{59461,59462} NF-L is comprised of an N-terminal domain that regulates neurofilament assembly, a central α-helical rod region that mediates dimerization, and a glutamic acid-rich C-terminal tail that is subject to phosphorylation.{59461,59463,59462} It is abundantly expressed in myelinated axons in the central and peripheral nervous systems and localizes to the cytoplasm, where it associates with an NF-middle (NF-M) or -heavy (NF-H) subunit to form parallel coiled-coil heterodimers.{59463} These heterodimers then associate in an anti-parallel manner to form tetramers, which assemble into NFs. Cerebrospinal fluid (CSF) NF-L levels have been used as a marker of axonal injury in a variety of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Parkinson’s disease, and Alzheimer’s disease.{59461} Mutations in NEFL, the gene encoding NF-L, have been found in patients with Charcot-Marie-Tooth disease type 2E (CMT2E), a neurological disease characterized by muscle weakness and atrophy.{59464} Cayman’s Neurofilament L (C-Term) Rabbit Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications.
Synonyms: Neurofilament Light Polypeptide|NF-L
Immunogen: Peptide from the C-terminal region of human neurofilament L
Formulation: 100 µl of protein A-affinity purified monoclonal antibody
Isotype: IgG
Applications: IHC and WB
Origin:
Stability: 365 days
Application|Immunohistochemistry||Application|Western Blot||Product Type|Antibodies|Monoclonal Antibodies||Research Area|Cell Biology|Cytoskeleton & Motor Proteins||Research Area|Immunology & Inflammation|Autoimmunity||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease
